T cell proteins like PD-1 are among the most hotly pursued and promising immuno-oncology targets, but Oncofactor Corp. believes drug developers are just scratching the surface of what proteins are involved in helping tumors avoid immune detection. The company is focusing on proteins expressed on cancer cells and has identified three targets that could offer better safety than targets on T cells and broader activity than some other tumor targets.

Oncofactor hopes to move a lead mAb into the clinic in 2016.